Genscript Biotech Balance Sheet Health
Financial Health criteria checks 4/6
Genscript Biotech has a total shareholder equity of $1.8B and total debt of $877.2M, which brings its debt-to-equity ratio to 48.1%. Its total assets and total liabilities are $3.3B and $1.5B respectively.
Key information
48.1%
Debt to equity ratio
US$877.17m
Debt
| Interest coverage ratio | n/a |
| Cash | US$1.88b |
| Equity | US$1.82b |
| Total liabilities | US$1.51b |
| Total assets | US$3.33b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GNNS.F's short term assets ($2.2B) exceed its short term liabilities ($533.0M).
Long Term Liabilities: GNNS.F's short term assets ($2.2B) exceed its long term liabilities ($974.7M).
Debt to Equity History and Analysis
Debt Level: GNNS.F has more cash than its total debt.
Reducing Debt: GNNS.F's debt to equity ratio has increased from 4.2% to 48.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GNNS.F has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GNNS.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.